title: Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1.
abstract: Eighteen patients with Stage 4 B-cell malignancies, which were primarily of intermediate or high grade and progressive despite multiple drug chemotherapy and external irradiation, were treated with fractionated doses of 131I-labeled Lym-1. Lym-1 is an IgG2a monoclonal antibody that was produced by immunizing mice with Raji cell nuclei that originated from a patient with African Burkitt's lymphoma. Despite advanced disease, 10 of the patients had objective evidence for a complete or partial remission. Toxicity was very modest except in one patient who developed hypotension. Dose-dependent hepatic uptake of Lym-1 was observed in the patients and in BALB/c mice suggesting receptor-mediated recognition of this murine antibody.
authors.affiliation: Department of Internal Medicine, University of California, Davis Medical Center, Sacramento 95817.
authors.forename: G L
authors.initials: GL
authors.lastname: DeNardo
authors.forename: S J
authors.initials: SJ
authors.lastname: DeNardo
authors.forename: L F
authors.initials: LF
authors.lastname: O'Grady
authors.forename: N B
authors.initials: NB
authors.lastname: Levy
authors.forename: G P
authors.initials: GP
authors.lastname: Adams
authors.forename: S L
authors.initials: SL
authors.lastname: Mills
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000032:analysis; D000911:Antibodies, Monoclonal / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007457:Iodine Radioisotopes / Q000008:administration & dosage* / Q000627:therapeutic use; D015448:Leukemia, B-Cell / Q000532:radiotherapy*; D008223:Lymphoma / Q000532:radiotherapy*; D008657:Metabolic Clearance Rate
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D007074:Immunoglobulin G; D007457:Iodine Radioisotopes